Article Text
Abstract
Introduction/Background Although much is known about the prevention, screening, and treatment of cervical cancer (CC), less is known about its humanistic burden. This study compared patient-reported outcomes (PROs) between women diagnosed and treated for CC, women diagnosed and untreated for CC, and women without CC.
Methodology Data were aggregated from the 2010, 2011, and 2013 EU5 National Health and Wellness Survey, a nationally-representative, self-administered, internet-based survey of adults (N=177,317). Controlling for baseline patient demographics and characteristics, three matched cohorts were compared in multivariable analysis: treated CC, untreated CC, and no CC. Respondents with other forms of cancer were excluded from analyses. Outcomes included Mental Component Summary (MCS) score, Physical Component Summary (PCS) score, and SF-6D Utility score from the Medical Outcomes Study 12-Item Version 2 Short Form Survey Instrument (SF-12v2). Suicidal ideation and depression were assessed via the Patient-Health Questionnaire 9-Item (PHQ-9).
Results Adjusted means are reported. Treated CC (N=113), untreated CC (N=646), and no CC (N=759) largely differed by PCS score (44.46 vs. 45.79 vs. 47.28, p’s<0.01) and SF-6D Utility score (0.65 vs. 0.67 vs. 0.69, p‘s<0.01), though the difference between treated CC and untreated CC was not significant. MCS score did not differ by cohort (figure 1). Untreated CC reported more depression than no CC, in terms of PHQ-9 score (6.99 vs. 5.82, p<0.05). PHQ-9 score did not differ by any other cohorts (figure 2). Treated CC was more likely to exhibit suicidal ideation than no CC (25.19% vs. 15.15%, p<0.05). Suicidal ideation did not differ by any other cohorts.
Conclusion Collectively, these results indicate that both treated CC and untreated CC patients experience a greater humanistic burden than women without CC. These differences highlight one aspect of the unmet needs of CC patients in the EU5, namely the humanistic burden they face.
Disclosure This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Chizoba Nwankwo is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Nate Way and Vicky Li are employees of Kantar Health, who received funding from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA to conduct this study.